If You Invested $1000 In Eli Lilly Stock 5 Years Ago, You Would Have This Much Today Eli Lilly (
NYSE:LLY ) has outperformed the market over the past 5 years by 25.47% on an annualized basis producing an average annual return of 37.22%. Currently, Eli Lilly has a market capitalization of $1.02 trillion.
Why Vivosim Labs Shares Are Rocketing on Wednesday? VivoSim Labs shares climbed after receiving a $5 million Eli Lilly milestone payment and forecasting more than 500% revenue growth in FY2027.
3 Vanguard ETFs Poised to Outperform as the Market Shifts Beyond Big Tech With investors finally embracing market segments beyond technology, these three Vanguard ETFs are winning.
2 Beaten-Down GLP-1 Stocks to Buy on the Dip Don't wait until clinical milestones send their share prices soaring.
Can Biogen Score Another Win In Alzheimer's Disease? Biogen and Ionis said Tuesday their tau-targeting Alzheimer's treatment slowed cognitive decline by 26% over 18 months.
Cathie Wood Bought $54 Million Worth Of SpaceX Stock Last Week Cathie Wood's ARK Invest was extremely active last week, adding SpaceX and Meta, while selling AMD and Robinhood stock.
Here's How Much Eli Lilly's Weight-Loss Drugs Are Worth to Investors Two drugs now generate almost two-thirds of the pharmaceutical giant's revenue.
Which is Best for Investors: Healthcare Stability (XLV) or Biotech Growth (IBBQ)? IBBQ surged 54.5% in one year but carries deeper drawdowns. XLV offers broader diversification, lower costs, and double dividend yield for steadier returns.
Which is the Better Choice for Healthcare Investors? IYH or BBH? BBH delivered 33.6% returns but swung 39.9% lower; IYH's 100 holdings offer steadier performance with 1.2% dividend yield.
3 Dividend Stocks That Are No-Brainer Buys Heading Into the Second Half of 2026 This is the list for you if you are looking for dividend stocks with attractive yields and well-supported dividends.
Is Pfizer on Track to Launch Its Next Lipitor -- This Time in the Weight-Loss Market? So far, Pfizer has been an also-ran in the GLP-1 race, but that could change if its long-acting weight-loss medication takes off.
IHE vs. IBB: Which iShares Healthcare ETF Is the Better Buy? Established pharmaceutical giants have delivered lower volatility and higher income than clinical-stage biotech exposure over the past five years.
Invesco Pharmaceuticals ETF vs State Street Biotech ETF: Which Fund Is the Better Buy in 2026? PJP delivers lower volatility and higher income with concentrated pharma exposure, while XBI offers broader biotech growth at lower cost.
Vanguard Health Care vs. VanEck Pharmaceutical: How Do These ETFs Stack Up? VHT offers broad diversification across 429 healthcare holdings, while PPH concentrates on 26 drugmakers for higher growth potential.
1 Unpopular Stock That Should Get More Attention and 2 That Underwhelm Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cord...
Invesco Pharmaceuticals ETF or First Trust Biotech Fund: Which Drug Maker-Focused Fund Should You Buy in 2026? PJP delivered stronger 5-year returns with lower volatility, while FBT offers broader biotech exposure at a slightly cheaper cost.
Is It Too Late to Buy Eli Lilly? The stock has soared 400% in recent years.
